Comparison of the effects of 2-chlorodeoxyadenosine and melphalan on myeloma cell lines

Leukemia Research

Volumn 20, Issue 2, 1996, Pages 155-160

  Hjertner, Öyvind ^a   Börset, Magne ^a   Waage, Anders ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

2 CdA; Melphalan; Multiple myeloma; Myeloma cell lines

Indexed keywords

CLADRIBINE; MELPHALAN;

ARTICLE; CELL CLONE; CELL DEATH; COLORIMETRY; COMPARATIVE STUDY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0343290261     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00128-X     Document Type: Article

References (17)

1. Piro L. D., Carrera C. J., Carson D. A. & Beutler E. (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117.
2. Estay E. H., Kurzrock R., Kantarjian H. M., O'Brian S. M., McCredie K. B., Beran M., Koller C., Keating M. J., Hirsch-Ginsberg C., Huh Y. O., Stass S. & Freireich E. J. (1992) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Blood 79, 882.
3. Saven A., Carrera C. J., Carson D. A., Beutler E. & Piro L. D. (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymph. (Suppl.) 133.
4. Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E. & Piro L. D. (1992) 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 10, 371.
5. Saven A., Carrera C. J., Carson D. A., Beutler E. & Piro L. D. (1992) 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80, 587.
6. Dimopoulos M. A., Kantarijan H. M., Estey E. H., O'Brian S., Delasalle K., Keating M. J., Freireich E. J. & Alexanian R. (1993) Treatment of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Intern. Med. 118, 195.
7. Dimopoulos M. A., Kantarjian H. M., Estay E. H. & Alexanian R. (1992) 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 80, 1626 (letter).
8. Niesvizky R., Siegel D. & Michaeli J. (1993) 2-Chlorodeoxyadenosine for multiple myeloma. Blood 81, 868 (letter).
9. Nagourney R. A., Evans S. S., Messenger J. C., Zhuang Su Y. & Weisenthal L. M. (1993) 2-Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br. J. Cancer 67, 10.
10. Nilsson K., Bennich H., Johanson S. G. O. & Pontén J. (1970) Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7, 477.
11. Matsuoka Y., Moore G., Yagi Y. & Pressman D. (1967) Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125, 1246.
12. Jackson N., Lowe J., Ball J., Bromidge E., Ling N. R., Larkins S., Griffith M. J. & Franklin I. M. (1989) Two new IgA1-k plasma cell lines (JJN-1 and JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin. Exp. Immunol. 75, 93.
13. Börset M., Waage A., Brekke O. L. & Helseth E. (1994) TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur. J. Haematol. 53, 31.
14. Børset M., Helseth E., Naume B. & Waage A. (1993). Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haematol. 85, 446.
15. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65, 55.
16. Liliemark J. & Juliusson G. (1991) On the pharmacokinetics of 2-chlorodeoxyadenosine in humans. Cancer Res. 51, 5570.
17. Woodhouse K. W., Hamilton P., Lennard A. & Rawlins M. D. (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur. J. Clin. Pharmacol., 24, 283.